Thalidomide abolishes transfusion-dependence in selected patients with myelodysplastic syndromes

Pellegrino Musto, Antonietta Falcone, Grazia Sanpaolo, Michele Bisceglia, Rosella Matera, Angelo Michele Carella

Research output: Contribution to journalArticlepeer-review

Abstract

Among 25 transfusion-dependent patients with myelodysplastic syndromes (MDS) receiving up to 300 mg/d thalidomide p.o., 5 became transfusion-free within 4-9 weeks and for 6 to +24 months. Responders had a recent diagnosis, normal karyotype, no excess of marrow blasts and were younger than non-responders. Thalidomide may be effective for treating anemia in selected MDS patients.

Original languageEnglish
Pages (from-to)884-886
Number of pages3
JournalHaematologica
Volume87
Issue number8
Publication statusPublished - 2002

Keywords

  • Anemia
  • Angiogenesis
  • Erythropoietin
  • Fetal hemoglobin
  • Myelodysplastic syndromes
  • Thalidomide

ASJC Scopus subject areas

  • Hematology

Fingerprint

Dive into the research topics of 'Thalidomide abolishes transfusion-dependence in selected patients with myelodysplastic syndromes'. Together they form a unique fingerprint.

Cite this